TrialAIDS (London, England)2011

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

Richard H Haubrich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.